Related Experiment Videos
Treatment of hyperlipidemia in human renal disease
1Department of Nephrology, S. Carlo Hospital, Milano, Italy.
Insights
Dyslipidemia in chronic kidney disease and nephrotic syndrome increases cardiovascular risk and kidney damage. Lipid-lowering therapies are essential to manage these conditions and prevent complications.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Dyslipidemia is linked to long-term cardiovascular complications in nephrotic syndrome and chronic renal insufficiency.
- This lipid imbalance can worsen glomerular damage through mechanisms similar to atherosclerosis.
Purpose of the Study:
- To emphasize the mandatory correction of hypercholesterolemia and hypertriglyceridemia in nephrotic syndrome and chronic renal insufficiency.
- To highlight therapeutic strategies for lipid management in these patient populations.
Main Methods:
- Dietary interventions combined with hypolipidemic drug administration.
- Specific drug classes recommended: hydroxymethylglutaryl coenzyme A (HMGCoA) reductase inhibitors for hypercholesterolemia and fibric acids for hypertriglyceridemia.
- Consideration of dialysis modality in end-stage renal failure.
Main Results:
- Combination therapy effectively addresses hypercholesterolemia and hypertriglyceridemia.
- Long-term administration of HMGCoA reductase inhibitors and fibric acids is effective.
- The role of extracorporeal LDL cholesterol removal remains uncertain.
Conclusions:
- Lipid management is crucial in nephrotic syndrome and chronic renal insufficiency to prevent cardiovascular events and kidney damage.
- Pharmacological and dietary interventions are key components of treatment.
- Further research is needed to clarify the benefits of specific interventions like extracorporeal LDL removal.
Abstract:
Existing evidence suggests that dyslipidemia associated with long-lasting nephrotic syndrome and with chronic renal insufficiency may favor in the long run the occurrence of cardiovascular complications, and also aggravate glomerular damage with a pathological mechanism analogous to atherosclerosis. Correction of hypercholesterolemia and hypertriglyceridemia is therefore mandatory in both clinical conditions. This goal can be achieved with the combination of dietary intervention and the administration, even for long periods of time, of hypolipemic drugs (hydroxymethylglutaryl coenzyme A, HMGCoA, reductase inhibitors, to correct hypercholesterolemia in nephrotic syndrome, and fibric acids, to correct hypertriglyceridemia in uremic and dialyzed patients are the drugs of choice). In end-stage renal failure, the choice of the type of dialysis is also important. The value of extracorporeal LDL cholesterol removal is still to be proven.